Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C DeRosa

Showing results (131-140 of 137) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 137 results.
Environmental Health Perspectives|August 1, 1996
Research needs for the risk assessment of health and environmental effects of endocrine disruptors: a report of the U.S. EPA-sponsored workshopR J Kavlock, G P Daston, C DeRosa, et al.
Journal of Virology|July 24, 2024
Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I allelesGeorge W Nelson, Janine van Duijn, Yuko Yuki, et al.
The Journal of Infectious Diseases|February 2, 2011
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesPaul A Goepfert, Marnie L Elizaga, Alicia Sato, et al.
Plos One|May 10, 2016
Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre StudyCatherine A Cosgrove, Charles J Lacey, Alethea V Cope, et al.
Frontiers in Immunology|May 29, 2025
Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccinesCassie G Ackerley, Srilatha Edupuganti, Chenchen Yu, et al.
The Journal of Infectious Diseases|January 10, 2014
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesPaul A Goepfert, Marnie L Elizaga, Kelly Seaton, et al.
Journal of AIDS & Clinical Research|November 21, 2015
Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive IndividualsJonathan D Fuchs, Pierre-Alexandre Bart, Nicole Frahm, et al.
Pageof 14

Showing results (131-140 of 137) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 137 results.
Environmental Health Perspectives|August 1, 1996
Research needs for the risk assessment of health and environmental effects of endocrine disruptors: a report of the U.S. EPA-sponsored workshopR J Kavlock, G P Daston, C DeRosa, et al.
Journal of Virology|July 24, 2024
Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I allelesGeorge W Nelson, Janine van Duijn, Yuko Yuki, et al.
The Journal of Infectious Diseases|February 2, 2011
Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesPaul A Goepfert, Marnie L Elizaga, Alicia Sato, et al.
Plos One|May 10, 2016
Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre StudyCatherine A Cosgrove, Charles J Lacey, Alethea V Cope, et al.
Frontiers in Immunology|May 29, 2025
Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccinesCassie G Ackerley, Srilatha Edupuganti, Chenchen Yu, et al.
The Journal of Infectious Diseases|January 10, 2014
Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particlesPaul A Goepfert, Marnie L Elizaga, Kelly Seaton, et al.
Journal of AIDS & Clinical Research|November 21, 2015
Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive IndividualsJonathan D Fuchs, Pierre-Alexandre Bart, Nicole Frahm, et al.
Pageof 14